Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
415 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Endometrial cancer
#NCT07044336
#2024-518777-34-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
AstraZeneca
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT05254743
#2023-507699-38-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Loxo Oncology
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04256317
Phase 3 monothérapie
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Chronic myelomonocytic leukemia (CMML)
Other MDS
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High
Very high
Required IPSS-M prognostic scores
High
Very high
Required molecular CPSS scores
Intermediate-2
High
Excluded previous treatments
Chemotherapy
3 recruiting sites
Taiho Oncology
Phase 3
Lymphoma
#NCT06284122
#2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min
< 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant
Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3
Stomach and esophageal cancer
#NCT06901531
#2024-519773-19-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3
Multiple myeloma
#NCT06918002
#2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
56 recruiting sites
Intergroupe Francophone du Myélome
Phase 3
Lung cancer
#NCT07291037
#2024-520101-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca
Phase 3
Multiple myeloma
#NCT05243797
#2023-510384-36-00
Required histologic types
Symptomatic multiple myeloma
Required number of previous lines of therapy
None
Required previous treatments
Monoclonal antibodies
Autologous stem cell transplant
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Car-T
9 recruiting sites
European Myeloma Network B.V.
Phase 3
Multiple myeloma
#NCT05623020
#2024-514139-50-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
4 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05623020
#2024-514139-50-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
1
2
Required previous treatments
Systemic Treatment-Naive
Proteasome inhibitor
Immunomodulator
4 recruiting sites
Pfizer